Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

91.33 +1.03 (+1.15%)
Streaming Delayed Price Updated: 10:48 AM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
3 S&P 500 Stocks Skating on Thin Ice
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte Corporation
Via Business Wire
News headline image
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
Top S&P500 movers in Friday's session ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
News headline image
Where Incyte Stands With Analysts ↗
 
Via Benzinga
News headline image
Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In ↗
Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis. 
Via Stocktwits
Topics Intellectual Property
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
Thursday's session: top gainers and losers in the S&P500 index ↗
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm. 
Via Investor's Business Daily
News headline image
Get insights into the top movers in the S&P500 index of Thursday's pre-market session. ↗
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday? 
Via Chartmill
News headline image
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
From Incyte
Via Business Wire
News headline image
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
News headline image
INCYTE CORP (NASDAQ:INCY) – A Biopharmaceutical Stock with Undervalued Potential ↗
INCYTE CORP (NASDAQ:INCY) shows strong valuation, profitability, and financial health, making it an interesting pick for value investors. The stock trades at a discount to peers with solid growth... 
Via Chartmill
News headline image
3 Low-Volatility Stocks with Questionable Fundamentals
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
3 Unpopular Stocks in Hot Water
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
News headline image
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Curious about the S&P500 stocks that are showing activity before the opening bell on Monday? 
Via Chartmill
News headline image
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses ↗
Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, supporting further development. 
Via Benzinga
News headline image
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism ↗
Stifel also upgraded the stock to ‘Buy’ with a $107 price target. 
Via Stocktwits
News headline image
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
From QIAGEN N.V.
Via Business Wire
News headline image
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
From Incyte
Via Business Wire
News headline image
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
From Incyte
Via Business Wire
News headline image
INCYTE CORP (NASDAQ:INCY) – A Potential Undervalued Opportunity in Biotech ↗
INCYTE CORP (NASDAQ:INCY) presents a compelling value case with strong profitability, low debt, and an attractive valuation. The biotech firm's fundamentals suggest potential upside for long-term... 
Via Chartmill
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
What's going on in today's session: S&P500 movers ↗
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
3 Mid-Cap Stocks with Questionable Fundamentals
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
News headline image
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
From Incyte
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.